Demographic and clinical characteristics of patients with incident gout included in analysis 2
| Initiators | Long-term users | |||
| Men n=359 | Women n=130 | Men n=2034 | Women n=882 | |
| Age, mean (SD), years | 65.1 (14.8) | 74.5 (13.3) | 66.1 (13.2) | 75.1 (11.0) |
| Follow-up, years, median (Q1, Q3) | 1.3 (0.3, 5.1) | 0.4 (0.2, 2.5) | 5.6 (3.3, 7.8) | 4.8 (2.9, 6.9) |
| Education level, years, N(%) | ||||
| <9 | 117 (32.6) | 66 (50.8) | 768 (37.8) | 459 (52.0) |
| 9–12 | 164 (45.7) | 48 (36.9) | 806 (39.6) | 291 (33.0) |
| >12 | 71 (19.8) | 12 (9.2) | 417 (20.5) | 119 (13.5) |
| Comorbidity index*, N(%) | ||||
| 0 | 93 (25.9) | 6 (4.6) | 449 (22.1) | 52 (5.9) |
| 1–2 | 140 (39.0) | 55 (42.3) | 908 (44.6) | 401 (45.5) |
| 3–4 | 93 (25.9) | 54 (41.5) | 534 (26.3) | 330 (37.4) |
| ≥5 | 33 (9.2) | 15 (11.5) | 143 (7.0) | 99 (11.2) |
| Medication†, N(%) | ||||
| Anticoagulants/platelet aggregation inhibitors | 136 (37.9)§ | 66 (50.8) | 959 (47.1) | 503 (57.0) |
| CV drugs‡ | 258 (71.9)§ | 115 (88.5)§ | 1612 (79.3) | 830 (94.1) |
| Cortisone | 150 (41.8)§ | 65 (50.0)§ | 187 (9.2) | 126 (14.3) |
*Based on number of ever diagnosed comorbidities during the follow-up. Comorbidities included: hypertension, diabetes, hyperlipidaemia, obesity, renal disease, heart failure, cardiomyopathy, psoriasis, chronic obstructive pulmonary disease, alcoholism, cerebrovascular disease, atherosclerotic disease and cancer.
†Defined as dispensed prescription within six months before the end of follow-up.
‡Drugs included: vasodilator drugs, anti-hypertensive drugs, diuretics, beta blockers, calcium antagonists and renin-angiotensin-aldosterone inhibitors.
§p <0.05 compared to long-term users.
CV, cardiovascular.